Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26.
The Agili-C implant supposts bone remodeling and cartilage regeneration, and it recieved FDA breakthrough designation in 2020, according to a news release. It is designed for International Cartilage Repair Society grade III or above knee-joint surface lesions.
"Agili-C is a technology I and others in the surgical community have been watching and waiting on for over 10 years," Dr. Zaslav said in the release. "It is a novel implant supported by 4-years of data and counting from the multinational, randomized and controlled IDE clinical trial. Agili-C offers a cost efficient, off-the-shelf implant to fill an unmet need in my clinical practice."